Ibogainalog
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ibogainalog (IBG), also known as 9-methoxyibogaminalog, is a non-selective serotonin receptor modulator, serotonergic psychedelic, and psychoplastogen of the ibogalog group related to the iboga alkaloid ibogaine but with a simplified chemical structure.
Ibogainalog (IBG), also known as 9-methoxyibogaminalog, is a non-selective serotonin receptor modulator, serotonergic psychedelic, and psychoplastogen of the ibogalog group related to the iboga alkaloid ibogaine but with a simplified chemical structure.
Pharmacology
Pharmacodynamics
Ibogainalog acts as a non-selective serotonin receptor modulator, including as an agonist of the serotonin 5-HT 1B , 5-HT 1F , 5-HT 2A , and 5-HT 6 receptors, as an agonist or antagonist of the serotonin 5-HT 2B and 5-HT 2C receptors, and as an inverse agonist of the serotonin 5-HT 7 receptor. Unlike noribogaine, IBG shows no activation of the opioid receptors or κ-opioid receptor agonism. In addition to its actions at serotonin receptors, IBG weakly inhibits certain nicotinic acetylcholine receptors. The drug also acts as a relatively weak serotonin reuptake inhibitor. The drug produces the head-twitch response in animals and hence shows psychedelic-like effects. However, it has reduced and relatively weak hallucinogen-like effects compared to 5-MeO-DMT. Conversely, tabernanthalog (TBG), a simplified analogue of tabernanthine and positional isomer of IBG, appears to be completely non-hallucinogenic. IBG shows comparable psychoplastogenic activity to ibogaine. In contrast to ibogaine, IBG and TBG appear to have much less or no potential for cardiotoxicity secondary to hERG inhibition. However, TBG showed a better overall safety profile than IBG and was selected for development instead of IBG. IBG shows analgesic effects against neuropathic pain and visceral pain in animals that appear to be mediated by serotonin 5-HT 2A receptor activation. In early animal studies, ibogainalog was described as having enhanced tryptamine-like, tremorogenic, and sedative effects compared to ibogaine. It was also said to have chlorpromazine-like effects.
Chemistry
IBG can be viewed as a conformationally restricted analogue of 5-MeO-DMT, whereas TBG can be viewed as a conformationally restricted analogue of 6-MeO-DMT. Owing to their simplified structures, the chemical syntheses of IBG and TBG are much more practical than the synthesis of ibogaine.
History
Ibogainalog was first described in the scientific literature by 1968. Subsequently, it was studied and described in greater detail by David E. Olson and colleagues in the 2020s.
Society and culture
Legal status
Canada
Ibogainalog is not an explicitly nor implicitly controlled substance in Canada as of 2025.
United States
Ibogainalog is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338231085 under CC BY-SA 4.0; modifications have been made.